Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nalinee Sangrujee

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Plos Medicine|July 18, 2012
HIV treatment as prevention: issues in economic evaluationTill Bärnighausen, Joshua A Salomon, Nalinee Sangrujee
Bulletin of the World Health Organization|April 5, 2014
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIVLisa O'Brien, Nathan Shaffer, Nalinee Sangrujee, et al.
Bulletin of the World Health Organization|April 27, 2004
Cost analysis of post-polio certification immunization policiesNalinee Sangrujee, Victor M Cáceres, Stephen L Cochi
Health Affairs (Project Hope)|May 12, 2005
Factors affecting U.S. manufacturers' decisions to produce vaccinesMargaret S Coleman, Nalinee Sangrujee, Fangjun Zhou, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
The costs of future polio risk management policiesRadboud J Duintjer Tebbens, Nalinee Sangrujee, Kimberly M Thompson
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2015
Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in BotswanaTyler Smith, Taraz Samandari, Taiwo Abimbola, et al.
Plos One|August 23, 2011
Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP)Julie R Harris, Barbara J Marston, Nalinee Sangrujee, et al.
Medgenmed : Medscape General Medicine|January 28, 2004
Policy decision options during the first 5 years following certification of polio eradicationNalinee Sangrujee, Radboud J Duintjer Tebbens, Victor M Cáceres, et al.
Vaccine|December 13, 2003
Cost-effectiveness of three different vaccination strategies against measles in Zambian childrenGustavo H Dayan, Lisa Cairns, Nalinee Sangrujee, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Global surveillance and the value of information: the case of the global polio laboratory networkEsther de Gourville, Radboud J Duintjer Tebbens, Nalinee Sangrujee, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Plos Medicine|July 18, 2012
HIV treatment as prevention: issues in economic evaluationTill Bärnighausen, Joshua A Salomon, Nalinee Sangrujee
Bulletin of the World Health Organization|April 5, 2014
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIVLisa O'Brien, Nathan Shaffer, Nalinee Sangrujee, et al.
Bulletin of the World Health Organization|April 27, 2004
Cost analysis of post-polio certification immunization policiesNalinee Sangrujee, Victor M Cáceres, Stephen L Cochi
Health Affairs (Project Hope)|May 12, 2005
Factors affecting U.S. manufacturers' decisions to produce vaccinesMargaret S Coleman, Nalinee Sangrujee, Fangjun Zhou, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
The costs of future polio risk management policiesRadboud J Duintjer Tebbens, Nalinee Sangrujee, Kimberly M Thompson
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2015
Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in BotswanaTyler Smith, Taraz Samandari, Taiwo Abimbola, et al.
Plos One|August 23, 2011
Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP)Julie R Harris, Barbara J Marston, Nalinee Sangrujee, et al.
Medgenmed : Medscape General Medicine|January 28, 2004
Policy decision options during the first 5 years following certification of polio eradicationNalinee Sangrujee, Radboud J Duintjer Tebbens, Victor M Cáceres, et al.
Vaccine|December 13, 2003
Cost-effectiveness of three different vaccination strategies against measles in Zambian childrenGustavo H Dayan, Lisa Cairns, Nalinee Sangrujee, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 23, 2006
Global surveillance and the value of information: the case of the global polio laboratory networkEsther de Gourville, Radboud J Duintjer Tebbens, Nalinee Sangrujee, et al.
Pageof 2